Cardiol Therapeutics Inc. stock is up 31.17% since 30 days ago. The next earnings date is Mar 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 4 December’s closed higher than November.
Cardiol Therapeutics Inc. focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD) Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study. The company is also developing a proprietary subcutaneous formulation of cannabidiol to achieve higher bioavailability.